Aurora Zanghì The widespread adoption of anti-CD20 monoclonal antibodies (anti-CD20 mAbs) in multiple sclerosis (MS) has prompted increasing interest in treatment discontinuation and de-escalation strategies. In this perspective, we critically examine current data o…
The management of multiple sclerosis (MS) in patients with significant comorbidities such as severe asthma presents unique therapeutic challenges. We report a case of successful combined biologic therapy with ofatumumab and mepolizumab in a patient wit…
Background and objectivesUblituximab, a novel, glycoengineered anti-CD20 monoclonal antibody, has recently entered clinical use for multiple sclerosis (MS). In this study, we aimed to delineate the longitudinal kinetics of circulating lymphocyte subset…
